{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:31:40Z","timestamp":1791909100201,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1127,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1124\/dmd.121.000442","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T16:50:14Z","timestamp":1631033414000},"page":"1070-1080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions"],"prefix":"10.1016","volume":"49","author":[{"given":"Shamema","family":"Nasrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy J.W.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadira X","family":"Perez-Paramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000442_bib1","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.3747\/co.23.3099","article-title":"Integrating cannabis into clinical cancer care","volume":"23","author":"Abrams","year":"2016","journal-title":"Curr Oncol"},{"key":"10.1124\/dmd.121.000442_bib2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1021\/acs.jnatprod.5b00949","article-title":"Evolution of the cannabinoid and terpene content during the growth of cannabis sativa plants from different chemotypes","volume":"79","author":"Aizpurua-Olaizola","year":"2016","journal-title":"J Nat Prod"},{"key":"10.1124\/dmd.121.000442_bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/2045125312457586","article-title":"Cannabis, a complex plant: different compounds and different effects on individuals","volume":"2","author":"Atakan","year":"2012","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1124\/dmd.121.000442_bib4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450","volume":"48","author":"Bansal","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000442_bib5","first-page":"985","article-title":"Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation","volume":"25","author":"Code","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000442_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj1370143","article-title":"A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors","volume":"137","author":"Cornish-Bowden","year":"1974","journal-title":"Biochem J"},{"key":"10.1124\/dmd.121.000442_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pharmthera.2019.05.001","article-title":"A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics","volume":"201","author":"Cox","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.121.000442_bib8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.105.009100","article-title":"Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform","volume":"34","author":"Dellinger","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000442_bib9","unstructured":"Food and Drug Administration (2020) In vitro drug interaction studies cytochrome P450 enzymes and transporter-mediated drug interactions."},{"key":"10.1124\/dmd.121.000442_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1037\/pha0000084","article-title":"Clinical applications of hallucinogens: a review","volume":"24","author":"Garcia-Romeu","year":"2016","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/dmd.121.000442_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jps.2600630705","article-title":"Physiochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol","volume":"63","author":"Garrett","year":"1974","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000442_bib12","series-title":"Innovative Approaches in Drug Discovery","first-page":"195","article-title":"Pharmacogenomics","author":"Ghodke-Puranik","year":"2017"},{"key":"10.1124\/dmd.121.000442_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s002130000657","article-title":"Bupropion SR worsens mood during marijuana withdrawal in humans","volume":"155","author":"Haney","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/dmd.121.000442_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/abbi.2000.1708","article-title":"Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver","volume":"376","author":"Hanna","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.121.000442_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/00498259009046849","article-title":"Metabolites of cannabidiol identified in human urine","volume":"20","author":"Harvey","year":"1990","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000442_bib16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug-drug interactions","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/dmd.121.000442_bib17","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0026-895X(24)12046-9","article-title":"CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants","volume":"28","author":"Hesse","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000442_bib18","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem Biodivers"},{"key":"10.1124\/dmd.121.000442_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-008-1260-2","article-title":"Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC","volume":"201","author":"Hunault","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/dmd.121.000442_bib19a","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000442_bib20","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1212\/01.WNL.0000130334.79514.EA","article-title":"Recreational use of phenytoin, marijuana, and alcohol: a case report","volume":"62","author":"Jessen","year":"2004","journal-title":"Neurology"},{"key":"10.1124\/dmd.121.000442_bib21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","article-title":"Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19","volume":"28","author":"Jiang","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000442_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","article-title":"Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes","volume":"89","author":"Jiang","year":"2011","journal-title":"Life Sci"},{"key":"10.1124\/dmd.121.000442_bib23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/ADM.0000000000000118","article-title":"Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans","volume":"9","author":"Manini","year":"2015","journal-title":"J Addict Med"},{"key":"10.1124\/dmd.121.000442_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/sni.sni_45_18","article-title":"Review of the neurological benefits of phytocannabinoids","volume":"9","author":"Maroon","year":"2018","journal-title":"Surg Neurol Int"},{"key":"10.1124\/dmd.121.000442_bib25","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/0024-3205(95)00193-A","article-title":"Metabolism of delta 9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys","volume":"56","author":"Matsunaga","year":"1995","journal-title":"Life Sci"},{"key":"10.1124\/dmd.121.000442_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/jat\/29.5.327","article-title":"Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC","volume":"29","author":"M\u00e9n\u00e9trey","year":"2005","journal-title":"J Anal Toxicol"},{"key":"10.1124\/dmd.121.000442_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.forsciint.2018.08.001","article-title":"Chemical profiling of the street cocktail drug \u2018nyaope\u2019 in South Africa using GC-MS I: stability studies of components of \u2018nyaope\u2019 in organic solvents","volume":"292","author":"Mthembi","year":"2018","journal-title":"Forensic Sci Int"},{"key":"10.1124\/dmd.121.000442_bib28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/01.ftd.0000177223.19294.5c","article-title":"Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract","volume":"27","author":"Nadulski","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.121.000442_bib29","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1373\/clinchem.2016.263475","article-title":"Free and glucuronide whole blood cannabinoids\u2019 pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake","volume":"62","author":"Newmeyer","year":"2016","journal-title":"Clin Chem"},{"key":"10.1124\/dmd.121.000442_bib30","doi-asserted-by":"crossref","unstructured":"Parihar V, Rogers A, Blain AM, Zacharias SRK, Patterson LL, Siyam MA-M (2020) Reduction in tamoxifen metabolites endoxifen and N-desmethyltamoxifen with chronic administration of low dose cannabidiol: a CYP3A4 and CYP2D6 drug interaction. J Pharm Pract 87-90.","DOI":"10.1177\/0897190020972208"},{"key":"10.1124\/dmd.121.000442_bib31","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1124\/dmd.111.038596","article-title":"An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes","volume":"39","author":"Parkinson","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000442_bib31a","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/dmd.118.085548","article-title":"Hepatic Enzymes Relevant to the Disposition of (-)-\u03949-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC","volume":"47","author":"Patilea-Vrana","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000442_bib32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.121.000442_bib33","doi-asserted-by":"crossref","first-page":"e00313","DOI":"10.1002\/prp2.313","article-title":"Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti-aromatase activity assay examining exemestane and its derivatives","volume":"5","author":"Peterson","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/dmd.121.000442_bib34","doi-asserted-by":"crossref","first-page":"e00314","DOI":"10.1002\/prp2.314","article-title":"In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17\u03b2-dihydroexemestane","volume":"5","author":"Peterson","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/dmd.121.000442_bib36","series-title":"Adv Pharmacol","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/bs.apha.2017.03.004","article-title":"Chapter Three - Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads","author":"Russo","year":"2017"},{"key":"10.1124\/dmd.121.000442_bib35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2174\/1871527316666170413105421","article-title":"Neurological disorders in medical use of cannabis: an update","volume":"16","author":"Solimini","year":"2017","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1124\/dmd.121.000442_bib37","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1373\/clinchem.2008.122119","article-title":"Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC","volume":"55","author":"Schwilke","year":"2009","journal-title":"Clin Chem"},{"key":"10.1124\/dmd.121.000442_bib38","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1373\/clinchem.2011.171777","article-title":"Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration","volume":"57","author":"Schwope","year":"2011","journal-title":"Clin Chem"},{"key":"10.1124\/dmd.121.000442_bib39","series-title":"Haddad and Winchester\u2019s Clinical Management of Poisoning and Drug Overdose","first-page":"97","article-title":"Drug Interactions","author":"Shannon","year":"2007"},{"key":"10.1124\/dmd.121.000442_bib40","first-page":"149","article-title":"Chemistry, metabolism, and toxicology of cannabis: clinical implications","volume":"7","author":"Sharma","year":"2012","journal-title":"Iran J Psychiatry"},{"key":"10.1124\/dmd.121.000442_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0379-0738(02)00023-3","article-title":"Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-\u0394(9)-carboxy tetrahydrocannabinol glucuronide","volume":"126","author":"Skopp","year":"2002","journal-title":"Forensic Sci Int"},{"key":"10.1124\/dmd.121.000442_bib42","doi-asserted-by":"crossref","first-page":"107937","DOI":"10.1016\/j.drugalcdep.2020.107937","article-title":"Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users","volume":"211","author":"Spindle","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/dmd.121.000442_bib43","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/clpt.1983.179","article-title":"Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women","volume":"34","author":"Wall","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000442_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.drugalcdep.2016.01.014","article-title":"Is cannabis use associated with an increased risk of onset and persistence of alcohol use disorders? A three-year prospective study among adults in the United States","volume":"161","author":"Weinberger","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/dmd.121.000442_bib45","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","article-title":"Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety","volume":"88","author":"Yamaori","year":"2011","journal-title":"Life Sci"},{"key":"10.1124\/dmd.121.000442_bib46","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.bcp.2010.01.028","article-title":"Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes","volume":"79","author":"Yamaori","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000442_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11419-011-0112-7","article-title":"Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids","volume":"29","author":"Yamaori","year":"2011","journal-title":"Forensic Toxicol"},{"key":"10.1124\/dmd.121.000442_bib48","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1124\/dmd.111.041384","article-title":"Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6","volume":"39","author":"Yamaori","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000442_bib49","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1345\/aph.1M064","article-title":"Probable interaction between warfarin and marijuana smoking","volume":"43","author":"Yamreudeewong","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.121.000442_bib50","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.addbeh.2005.02.005","article-title":"Side effects of dextromethorphan abuse, a case series","volume":"30","author":"Ziaee","year":"2005","journal-title":"Addict Behav"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:04:38Z","timestamp":1740765878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624080164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0090955624080164"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000442","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The Author(s)","name":"copyright","label":"Copyright"}]}}